Atlas Trials

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Clinical trial NCT02005289 · COMPLETED

Trial details

NCT number
NCT02005289
Sponsor
Ohio State University Comprehensive Cancer Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Contiguous Stage II Small Lymphocytic LymphomaNoncontiguous Stage II Small Lymphocytic LymphomaProlymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaStage I Small Lymphocytic LymphomaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic LeukemiaStage III Small Lymphocytic LymphomaStage IV Chronic Lymphocytic LeukemiaStage IV Small Lymphocytic Lymphoma
Start date
2014-01-17
Primary completion
2025-05-20
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.